CA-VISA-INC
27.10.2021 13:02:44 CEST | Business Wire | Press release
As consumer demand for 'Buy Now, Pay Later' (BNPL) solutions continues to grow, Visa (NYSE: V) today announced a growing list of issuers, acquirers and fintechs that are leveraging Visa’s technology — both its network-based Visa Installments Solution and its longstanding fintech solutions — to bring ‘Buy Now, Pay Later’ options to their customers.
A recent Visa study found that nearly half of all global consumers (42%) expressed interest in installment financing that is offered on their existing credit card or one they could apply for.1 To help partners meet this demand, Visa Installments Solution is being deployed globally to make issuer-offered BNPL options available in-store and across ecommerce channels. With the network-based solution, financial institutions can add BNPL as a customized feature for credit card holders, on their already approved credit lines. And likewise, acquirers on the network can activate the ability to enable installments for any of their retailers that accept Visa. First launched as a pilot in 2019, the solution has expanded to Australia, Canada, Malaysia, Russia and the U.S.
In North America, Visa is collaborating with Canada’s Moneris , and working with CIBC , Commerce Bank , Desjardins Group (Desjardins) , Equinox Payments , i2c , ScotiaBank and Versapay . In Asia Pacific, following the recent launch with HSBC , Visa is rolling out installment programs with ANZ , GHL Systems Malaysia and Quest Payment Systems . And in Russia, Visa has partnered with Home Credit Bank and Russian Standard Bank . Visa is also working with Cybersource , FIS , Global Payments and TSYS, a Global Payments company, in several markets across the globe to enable the Visa Installments Solution.
The global rollout of Visa Installments Solution complements Visa’s existing support of today’s leading BNPL fintechs, including: Afterpay , ChargeAfter , Klarna , Paidy , Sezzle , SplitIt and Zip . Since 2017, Visa’s fintech solutions have helped fintechs grow by: issuing digital credentials or virtual cards, so consumers can seamlessly use installments at checkout; leveraging Visa’s acceptance and reach with sellers; and taking advantage of the security and risk offerings Visa provides. Additionally, this week Visa announced that Klarna has signed a global brand deal with Visa to accelerate its expansion and scale in several markets.
“For years, Visa has been enthusiastically embracing BNPL for the same reason we pioneered revolving credit, debit and prepaid decades ago: because it expands choice and convenience for buyers and sellers alike,” said Mary Kay Bowman, SVP and global head of payment and platform products, Visa. “If shoppers prefer a BNPL fintech solution, we are here and enabling it; if they want an option from their banks, we’re helping offer those too.”
Visa’s recent survey showed that future interest in installment plans is high and outpaces current adoption in all countries tested, underscoring the strong opportunity for BNPL usage looking ahead.2 Research shows that when BNPL options are available at checkout, retailers also benefit from an increase in spend and see more shoppers completing their purchases.
“At HSBC we strive to bring new and innovative solutions to our customers. We are excited to partner with Visa and be the first bank outside North America to launch the Visa Installments Solution, starting in Malaysia; announcing our entrance in the digital Buy Now, Pay Later space,” said Madhu Kejriwal, Group Head, Unsecured Lending & Partnerships, HSBC Wealth & Personal Banking. “This feature facilitates point of sale purchases for HSBC Visa credit card customers when they shop with partner merchants, by allowing them to split payments into monthly instalments at no additional cost and no credit application. We look forward to continuing to innovate with Visa, including delivering on our global BNPL strategy.”
“BNPL solutions have emerged as a must-have capability for both card issuers and merchants across the globe. We are thrilled to partner with Visa and to add Visa Installments to our existing BNPL product offering for our issuers and their cardholders," said Ava Kelly, Global Head of Products of Silicon Valley-based i2c, a global Visa Ready and Fast Track member.
“We’re happy to be working with a trusted brand like Visa on providing a Buy Now, Pay Later option to Canadians,” said Patrick Diab, Chief Product and Partnership Officer, Moneris. “Bringing flexible payment methods like Buy Now, Pay Later to our merchants helps them offer their customers more options when it comes time to pay.”
“We are very pleased to partner with Visa on BNPL,” said Craig O’Neill, CEO of Versapay. “As a payment facilitator, we were able to seamlessly onboard merchants into the Visa program, and as the BNPL market matures, we see this becoming an attractive offering for business to business commerce, an area Versapay intimately knows and serves well.”
For more information on Visa Installments, visit: https://usa.visa.com/partner-with-us/payment-technology/installments.html
About Visa
Visa Inc. (NYSE: V) is the world’s leader in digital payments. Our mission is to connect the world through the most innovative, reliable and secure payment network - enabling individuals, businesses and economies to thrive. Our advanced global processing network, VisaNet, provides secure and reliable payments around the world, and is capable of handling more than 65,000 transaction messages a second. The company’s relentless focus on innovation is a catalyst for the rapid growth of digital commerce on any device for everyone, everywhere. As the world moves from analog to digital, Visa is applying our brand, products, people, network and scale to reshape the future of commerce. For more information, visit About Visa , visa.com/blog and @VisaNews .
1 Visa & Growth from Knowledge Survey, September 2021 (Results from 7-market global survey in Australia, Canada, Hong Kong, Russia, U.S., U.K.)
2 Visa & Growth from Knowledge Survey, September 2021 (Results from 7-market global survey in Australia, Canada, Hong Kong, Russia, U.S., U.K.)
View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005406/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Danish C-UAS Startup Shotling Raises €700K Oversubscribed Pre-Seed (Myriad-IPO CLUB-EIFO) for Anti-Drone Shotgun2.2.2026 07:35:00 CET | Press release
Shotling, a Danish defense technology startup specializing in kinetic short-range counter-UAS (C-UAS) systems, today announced the closing of a pre-seed financing round with €700K committed out of a targeted €500K. The round is led by Myriad Defense Fund, with co-investment from IPO CLUB’s Fund II America 2030, and a non-dilutive match-loan granted by EIFO, the Export and Investment Fund of Denmark, supporting Shotling’s mission to deliver rapid-fire modular shotgun systems against FPV drones and loitering munitions—as the global counter-UAS market accelerates towards $10B by 2030, with kinetic defense segment showing strong momentum (25%+ CAGR). Shotling’s rotary shotgun system provides unmatched close-range defense (50–100m) against the rapidly growing threat of kamikaze drones, combining a gatling-style design, with novel, high-capacity magazines, and firing rates up to 3,000 RPM using standard or tungsten-based 12-gauge shells. With deep expertise in weapons engineering and active
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 07:00:00 CET | Press release
The United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults RelabotulinumtoxinA is designed to optimize molecule integrity to deliver fast onset of action as early as Day 1 and sustained results for six months for frown lines and crow’s feet and has been approved in over 20 markets, including in the European Union1-3 Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation
High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 20261.2.2026 08:00:00 CET | Press release
Lorient, a premium aesthetic brand, announced that it has drawn global attention at the 27th IMCAS World Congress 2026 in Paris, attracting over 15,000 professionals and demonstrating its leadership in aesthetic innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131322203/en/ Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibility (Image: Lorient) The highlight was a session led by Dr. Jani van Loghem, a globally revered key opinion leader known for establishing international aesthetic safety protocols. His involvement provided a prestigious validation of the technical excellence of Lorient. Alongside him, prominent Korean medical experts Dr. Won Lee and Dr. Do Young Rhee shared clinical insights that drew widespread praise from the international medical community. Central to the academic discussions was Lorient’s "safety-first" philosophy for its premium HA filler ran
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
